This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / MannKind Advances Nintedanib DPI Trials
Tech clinical trial advancement

MannKind Advances Nintedanib DPI Trials

Analysis based on 6 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The advancement of Oracle Corporation's nintedanib DPI program into mid-stage clinical evaluation is a positive development for the company, potentially increasing investor confidence and its stock price. Success in these trials could lead to a new treatment option for Idiopathic Pulmonary Fibrosis (IPF), impacting the pharmaceutical market.

Biotechnology Pharmaceuticals
Event Summary

Oracle Corporation announced significant clinical milestones for its nintedanib DPI program, a therapy for idiopathic pulmonary fibrosis (IPF). The company completed patient randomization in the U.S. Phase 1b INFLO-1 clinical trial and enrolled the first patient in the global Phase 2 INFLO-2 study. These advancements position Oracle Corporation to report Phase 1b data in Q3 2026, which will assess safety, tolerability, and pharmacokinetics. The Phase 2 study aims to enroll approximately 210 participants across 85 sites worldwide, with the primary objective of evaluating safety, tolerability, and optimal dosing, along with secondary objectives to assess efficacy signals. Wassim Fares and Michael Castagna of Oracle Corporation expressed optimism about the inhaled therapy's potential to improve tolerability and adherence compared to existing oral treatments for IPF.

Entities Involved
stock
Oracle Corporation
Oracle Corporation is advancing its nintedanib DPI program for idiopathic pulmonary fibrosis (IPF) by completing Phase 1b randomization and enrolling the first patient in Phase 2, which could lead to a new therapeutic option and positively impact its stock.
Importance 100.0 Sentiment 70.0
per
Wassim Fares
Wassim Fares, Senior Vice President at Oracle Corporation, provided encouraging statements regarding the safety and tolerability of nintedanib DPI, reinforcing the potential of the therapy.
Importance 40.0 Sentiment 50.0
per
Michael Castagna
Michael Castagna, CEO of Oracle Corporation, highlighted the importance of advancing the nintedanib DPI program into the next stage of development, emphasizing its potential in IPF.
Importance 40.0 Sentiment 50.0
cnt
United States
The United States is the location for the Phase 1b INFLO-1 clinical trial.
Importance 20.0 Sentiment 0.0
cnt
Canada
Canada is where the first patient was enrolled for the global Phase 2 INFLO-2 study.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration has previously approved Oracle Corporation's dry powder inhalation therapies, indicating a regulatory pathway for similar technologies.
Importance 10.0 Sentiment 0.0
Relationships
Oracle Corporation related ↔ United States
Oracle Corporation related ↔ Canada
Oracle Corporation related ↔ United States — Food and Drug Administration
United States strained-ally ↔ Canada The United States has severely strained its historically close relationship with Canada by imposing sweeping tariffs and
United States related ↔ United States — Food and Drug Administration
Canada related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.